PMID- 32441679
OWN - NLM
STAT- MEDLINE
DCOM- 20210805
LR  - 20210805
IS  - 1538-067X (Electronic)
IS  - 1092-1095 (Linking)
VI  - 24
IP  - 3
DP  - 2020 Jun 1
TI  - Durvalumab Immunotherapy: Nursing Management of Immune-Related Adverse Events 
      During the Journey of Patients With Stage III Non-Small Cell Lung Cancer.
PG  - 277-283
LID - 10.1188/20.CJON.277-283 [doi]
AB  - BACKGROUND: When resection is not an option, platinum-based chemoradiotherapy 
      (CRT) has been the historic standard of care in non-small cell lung cancer 
      (NSCLC). Prognosis remains poor with CRT alone. Durvalumab has shown significant 
      improvement (versus placebo) in progression-free and overall survival in patients 
      with unresectable stage III NSCLC without progression following CRT. OBJECTIVES: 
      This article aims to provide an overview of the efficacy and safety outcomes with 
      durvalumab in patients with stage III NSCLC and identify management strategies 
      for potential adverse events (AEs). METHODS: A review of published literature and 
      guidelines was performed to evaluate durvalumab clinical outcomes and AE 
      management strategies. FINDINGS: Durvalumab has established efficacy in patients 
      with unresectable stage III NSCLC and is now the standard of care following CRT. 
      Nurses need to be trained to recognize potential immune-related AEs in patients 
      treated with immune checkpoint inhibitors.
FAU - Davies, Marianne
AU  - Davies M
AUID- ORCID: 0000-0002-8567-536X
AD  - Yale Comprehensive Cancer Center.
FAU - Duffield, Emily
AU  - Duffield E
AD  - Smilow Cancer Hospital at Yale-New Haven Hospital.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin J Oncol Nurs
JT  - Clinical journal of oncology nursing
JID - 9705336
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antineoplastic Agents, Immunological)
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibodies, Monoclonal/adverse effects/*therapeutic use
MH  - Antineoplastic Agents, Immunological/adverse effects/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*nursing/*therapy
MH  - Drug-Related Side Effects and Adverse Reactions/*nursing
MH  - Female
MH  - Humans
MH  - Immunotherapy
MH  - Lung Neoplasms/*nursing/*therapy
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Oncology Nursing/*standards
MH  - Practice Guidelines as Topic
MH  - Prognosis
OTO - NOTNLM
OT  - NSCLC
OT  - durvalumab
OT  - immune checkpoint inhibitors
OT  - immunotherapy
OT  - nurse
EDAT- 2020/05/23 06:00
MHDA- 2021/08/06 06:00
CRDT- 2020/05/23 06:00
PHST- 2020/05/23 06:00 [entrez]
PHST- 2020/05/23 06:00 [pubmed]
PHST- 2021/08/06 06:00 [medline]
AID - 10.1188/20.CJON.277-283 [doi]
PST - ppublish
SO  - Clin J Oncol Nurs. 2020 Jun 1;24(3):277-283. doi: 10.1188/20.CJON.277-283.